Key Highlights

● FG Nexus exited its Ethereum treasury strategy in mid-2026 and completed a 1-for-5 reverse split as it pivots toward real estate and merchant banking.

● Prenetics disclosed a $1 billion growth-financing arrangement with General Catalyst and raised full-year Revenue guidance into a $220 million to $230 million range.

● OIO Group rebranded from a waste-recycling Business and is now pursuing a combination with Italian automaker De Tomaso Automobili after a 1-for-3 reverse split.

● Strive, formerly Asset Entities, runs an asset-management business built around an aggressive Bitcoin accumulation strategy and a structured income security called SATA.

Five small-cap Nasdaq tickers heading into autumn 2026 share little beyond their exchange listing, spanning crypto-treasury strategies, a luxury-auto pivot, a consumer-health growth story and an oncology drug developer, each mid-transformation and worth understanding on its own terms.

Five Companies Mid-Transformation

A mixed basket like FG Nexus (NASDAQ: FGNX), Prenetics Global (NASDAQ: PRE), OIO Group (NASDAQ: OIO), Strive (NASDAQ: ASST) and Apollomics (NASDAQ: APLM) spans a crypto-treasury company in transition, a consumer health-sciences brand, a former industrial recycler turned hypercar venture, a Bitcoin-treasury asset manager, and a clinical-stage cancer-drug developer. What ties them together is not a shared industry but a shared moment: each has been through a significant corporate reinvention within the past year, and each carries the Volatility that comes with it.

Working from company disclosures and market aggregators, the picture that emerges is one of small-cap businesses rewriting their own stories in real time, some through crypto exposure, others through outright changes of industry.

A Stretch Defined by Reinvention and Risk

Two of these five names are tied to the 2025-2026 wave of digital-asset treasury companies, small public firms that raised Capital to hold Bitcoin or Ethereum on the Balance Sheet in hopes the market would value the coins at a premium to net asset value. That trade cut both ways in 2026: some treasuries compounded, while others became forced sellers once share prices fell below the value of their holdings.

The remaining names show a different kind of risk. Reverse splits, private placements, corporate rebrands and compliance notices recur across the group, the fingerprints of high-mortality small-cap reinvention. Investors weighing any of these tickers are really weighing execution risk and dilution, not a single sector story.

FG Nexus Inc. (NASDAQ:FGNX): An Ethereum Treasury That Chose the Exit

FG Nexus was renamed from Fundamental Global Inc. in July 2025 when it launched an Ethereum treasury strategy backed by a roughly $200 million private placement, according to its own announcements. That thesis unwound quickly.

Reporting indicates the company accumulated around 50,000 ETH by September 2025, then reversed course: its board authorized an exit from the digital-asset business in June 2026, and it sold its entire remaining Ethereum position, roughly 30,000 ETH, before June 30, raising close to $61 million. Reported stockholders' Equity fell by more than half over six months.

FG Nexus is now steering toward real estate and merchant banking, with a special committee reviewing a possible combination with FG Communities, a manufactured-housing venture. A 1-for-5 reverse split took effect in February 2026. The shares changed hands near $8 in mid-September, with a Market Value around $42 million. This is a company mid-transformation, and its past ETH thesis should be treated as closed rather than core to the current story.

Prenetics Global Limited (NASDAQ:PRE): Consumer Health on an Aggressive Growth Track

Prenetics is a Hong Kong-founded consumer health-sciences company, best known lately for its IM8 longevity-supplement brand. The recent news flow is genuinely eventful for a company its size. Prenetics disclosed a $1 billion growth-financing arrangement with General Catalyst in July 2026, reported strong year-over-year growth for IM8, and raised full-year revenue guidance into a $220 million to $230 million range, according to summaries of its releases. The shares traded in the low-to-mid $20s in September.

Prenetics is a health-and-wellness growth story with an aggressive Marketing engine, and its risks, customer Acquisition costs, Brand durability, and cash burn against ambitious guidance, are consumer risks rather than financial-sector ones. It merits a watchlist for growth-focused investors tracking how the General Catalyst financing translates into sustained IM8 momentum.

OIO Group Limited (NASDAQ:OIO): From Industrial Recycling to Ultra-Luxury Autos

OIO Group is the former ESGL Holdings, a Singapore-based industrial-waste recycling company that rebranded in early 2026. Its transformation ran toward ultra-luxury automobiles: reporting describes a 2026 combination with De Tomaso Automobili, the storied Italian marque, with work on a V12 engine programme and the limited-run P72.

The company completed a 1-for-3 reverse split in April 2026. Aggregator data shows a low nominal share price alongside a large reported share count, which makes its headline market-cap figure look unstable and worth treating cautiously until fresh filings confirm the post-combination structure.

OIO's recent corporate history is a clear example of a Nasdaq-listed shell being repurposed for an entirely new business. The interesting question going forward is execution on cars and capital, a very different risk bucket than the one the company occupied a year ago.

Strive, Inc. (NASDAQ:ASST): The Bitcoin Treasury Behind the Asset Manager

Strive is the largest of the five by market value. The ticker is a legacy of Asset Entities Inc., the small social-media and marketing firm that combined with Vivek Ramaswamy-founded Strive Asset Management in a deal completed in 2025 to create what the companies billed as the first publicly traded asset-management Bitcoin treasury company.

Strive runs an exchange-traded-fund and portfolio-management business layered on top of an aggressive Bitcoin accumulation strategy. Reporting from mid-September 2026 points to holdings in the region of 25,000 BTC, with public statements describing a Bitcoin Stewardship Commitment adopted in July 2026. The company has also introduced a structured security, SATA, marketed around daily cash distributions.

By aggregator data, the stock traded near $27 in mid-September with a market Capitalization around $2.4 billion, far above the other names in this group. That scale cuts both ways: the equity effectively behaves as a leveraged Bitcoin proxy wrapped in an asset manager, and reported quarterly revenue remains modest relative to the market cap.

Apollomics Inc. (NASDAQ:APLM): A Clinical-Stage Oncology Developer

Apollomics is a clinical-stage biopharmaceutical company developing oncology therapies, immune-system and molecular-pathway drugs aimed at cancer. Its profile carries the classic small-cap biotech risks.

Reporting indicates Apollomics received a Nasdaq notice in June 2026 over a minimum-market-value shortfall, then regained compliance by July 2026, and it has leaned on repeated small financings, including a roughly $10 million private Placement in August 2026 and earlier bridge funding. Losses remain heavy against limited revenue.

For a biotech, the catalysts that matter are clinical data, regulatory milestones and the ability to fund trials without crushing dilution. Its recent compliance scare underlines how quickly a thinly capitalized developer can brush against delisting thresholds, making cash runway as important a metric as any trial readout.

What Investors Should Watch

On FG Nexus, the questions are whether the FG Communities combination proceeds, how the balance sheet stabilizes after the ETH exit, and whether merchant banking can generate real recurring revenue. On Strive, everything tracks Bitcoin: the coin's price, the pace of further purchases, any dilution used to fund them, and whether the asset-management business grows into the valuation rather than simply riding the treasury.

For the other three, the watch items sit in different corners: hypercar production and financing at OIO Group; supplement-brand Economics and how the General Catalyst financing is deployed at Prenetics; and clinical data, funding and continued Nasdaq compliance at Apollomics.

Across all five, the structural warning signs recur, reverse splits, private placements, and strategy pivots, and position sizing should reflect the elevated risk that comes with small-cap reinvention.

Five Stories Worth Tracking Individually

None of these five companies looks today the way it looked eighteen months ago. FG Nexus has walked away from a crypto treasury it built just a year earlier. OIO Group has left industrial recycling behind for hypercars. Strive has turned a small marketing firm into a Bitcoin-backed asset manager. Prenetics is scaling a supplement brand on the back of a billion-dollar financing arrangement, and Apollomics is pushing oncology candidates through trials while managing a thin cash position.

The common thread is reinvention under pressure, whether that pressure comes from a market downturn, a strategic rethink, or the simple need to fund the next stage of growth. Each company's near-term catalysts, a real estate combination, a production ramp, a trial readout, a financing drawdown, are specific to its own business and should be evaluated as such.

Investors following any of these names would do well to treat the past year's history as context rather than a template for what comes next, since each company is now operating under a substantially different plan than the one that first brought it public attention.